Q2 FY27 revenue rises, but consolidated margin and profit fall
STYRENIX · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.4 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Q2 FY27 standalone income rose 26.7% to INR 781.1 crore, with PAT up 0.8% to INR 51.2 crore. Consolidated income rose 24.4% to INR 997.3 crore, but EBITDA fell 14.5% to INR 75.6 crore and PAT dropped 48.2% to INR 23.2 crore; margin eased to 7.6% from 11.0%. H1 PAT rose 78% standalone and 67% consolidated. Management cited volatile input costs and Thailand overcapacity. The 50 KT ABS expansion remains on track for H2 FY27.
Revenue and H1 profit growth help, but weak Q2 margins and Thailand pressure may cap near-term stock gains. New ABS capacity supports growth.